Dr. Candida Fratazzi is a clinical strategy and trial design specialist with more than 25 years of experience. Her work led to market approval of therapies such as Velaglucerase alpha® (Shire), Replagal® (Shire), Lipoprotamase (Alnara) and Tigecycline® IV (Wyeth). She is a recognized expert in the development of orphan indications and rare disease therapies. Dr. Fratazzi founded BBCR in 2009. Previously she served as senior medical leader at Altus, Shire HGT, Johnson & Johnson and Wyeth Pharmaceuticals. Throughout her carrier, Dr. Fratazzi has developed and presented clinical strategies for many drug candidates. She has devoted special attention to drug safety and risk management. She has also served on the medical faculties of Harvard and John Hopkins Universities as well as Imperial College (UK). She has co-authored more than 50 scientific papers in peer review journals and is currently a reviewer for specialized journals including Biologics: Target & Therapy; Biosimilars; Drug Design, Development and Therapy; Clinical Interventions in Aging.